Clinical Scorecard: Comparison of Pharmacokinetic-Based and Weight-Based Coagulation Factor Replacement in Hemophilia Patients Undergoing Joint Arthroplasty: A Retrospective Analysis of Perioperative Bleeding Risks and Economic Implications

At a Glance

Key Highlights

• PK-guided therapy reduced median hospitalization costs compared to weight-guided therapy.
• Lower median coagulation factor consumption observed in the PK-guided group.
• No significant increase in perioperative bleeding risk with PK-guided therapy.

Guideline-Based Recommendations

Diagnosis

• Diagnosis of hemophilia based on clinical manifestations, coagulation function tests, and genetic testing.

Management

• Coagulation factor replacement therapy should be guided by WFH guidelines.

Monitoring & Follow-up

• Quality of life assessed using SF-6Dv2 instrument preoperatively and at 12-month follow-up.

Risks

• Higher perioperative bleeding risk in hemophilia patients compared to standard orthopedic surgery.

Patient & Prescribing Data

Thirty-three male patients with a median age of 39 years, predominantly with severe hemophilia.

PK-guided therapy introduced in 2020 showed clinical and economic advantages.

Clinical Best Practices

• Utilize PK-guided coagulation factor replacement to optimize treatment outcomes.
• Adhere to WFH guidelines for dosing and management of hemophilia patients.

Related Resources & Content

• World Federation of Hemophilia guidelines